Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma

被引:11
|
作者
Laukhtina, Ekaterina [1 ,2 ]
Pradere, Benjamin [1 ,3 ]
D'Andrea, David [1 ]
Rosiello, Giuseppe [4 ,5 ,6 ]
Luzzago, Stefano [4 ,7 ]
Pecoraro, Angela [4 ,8 ]
Palumbo, Carlotta [4 ,9 ,10 ]
Knipper, Sophie [4 ,11 ]
Karakiewicz, Pierre, I [4 ]
Margulis, Vitaly [12 ]
Quhal, Fahad [1 ,13 ]
Sari Motlagh, Reza [1 ]
Mostafaei, Hadi [1 ,14 ]
Mori, Keiichiro [1 ,15 ]
Schuettfort, Victor M. [1 ,16 ]
Enikeev, Dmitry [2 ]
Shariat, Shahrokh F. [1 ,2 ,12 ,17 ,18 ,19 ,20 ,21 ]
机构
[1] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, Vienna, Austria
[2] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[3] Univ Hosp Tours, Dept Urol, Tours, France
[4] Univ Montreal Hlth Ctr, Div Urol, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[5] IRCCS San Raffaele Sci Inst, Dept Urol, Milan, Italy
[6] IRCCS San Raffaele Sci Inst, Div Expt Oncol, Urol Res Inst URI, Milan, Italy
[7] IRCCS, Dept Urol, European Inst Oncol, Milan, Italy
[8] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy
[9] ASST Spedali Civili Brescia, Dept Med & Surg Specialties, Urol Unit, Brescia, Italy
[10] Univ Brescia, Radiol Sci & Publ Hlth, Brescia, Italy
[11] Univ Hosp Hamburg Eppendorf, Martini Klin Prostate Canc Ctr, Hamburg, Germany
[12] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[13] King Fahad Specialist Hosp, Dept Urol, Dammam, Saudi Arabia
[14] Tabriz Univ Med Sci, Res Ctr Evidence Based Med, Tabriz, Iran
[15] Jikei Univ, Dept Urol, Sch Med, Tokyo, Japan
[16] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany
[17] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[18] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[19] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[20] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Div Urol, Amman, Jordan
[21] European Assoc Urol Res Fdn, Arnhem, Netherlands
来源
MINERVA UROLOGY AND NEPHROLOGY | 2022年 / 74卷 / 03期
关键词
Renal cell carcinoma; Neoplasm metastasis; Cytoreduction surgical procedures; Nephrectomy; Survival; Mortality; LYMPHOCYTE RATIO; SURVIVAL; MODEL;
D O I
10.23736/S2724-6051.21.04023-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Identifying those of patients with metastatic renal cell carcinoma (mRCC) who are most likely to benefit from cytoreductive nephrectomy (CN) is challenging. We tested the association between preoperative value of Systemic Immune-Inflammation Index (SII) and overall survival (OS) as well as cancer-specific survival (CSS) in mRCC patients treated with CN. METHODS: mRCC patients treated with CN at different institutions were included. After assessing for the optimal pretreatment SII cut-off value, we found 710 to have the maximum Youden Index value. The overall population was therefore divided into two SII groups using this cut-off (low, <710 vs. high, >= 710). Univariable and multivariable Cox regression analyses tested the association SII and OS as well as CSS. The discrimination of the model was evaluated with the Harrel's Concordance Index (C-Index). The clinical value of the SII was evaluated with decision curve analysis (DCA). RESULTS: Among 613 mRCC patients, 298 (49%) patients had a SII>710. Median follow-up was 31 (IQR 16-58) months. On univariable analysis, high preoperative serum SII was significantly associated with worse OS (HR: 1.28, 95% CI: 1.07-1.54, P=0.01) and CSS (HR: 1.29, 95% CI: 1.08-1.55, P=0.01). On multivariable analysis, which adjusted for the effect of established clinicopathologic features, SII >= 710 was associated with OS (HR: 1.25, 95% CI: 1.04-1.50, P=0.02) and CSS (HR: 1.26, 95% CI: 1.05-1.52, P=0.01). The addition of SII only slightly improved the discrimination of a base model that included established clinicopathologic features (C-index: 0.637 vs. 0.629). On DCA, the inclusion of SII did not improve the net-benefit of the prognostic model. On multivariable analyses, SII >= 710 remained independently associated with the worse OS and CSS in IMDC intermediate risk group (both: HR: 1.31, 95% CI: 1.02-1.67, P=0.03). In the subgroup analyses based on the BMI, among patients with BMI 25, SII was significantly associated with OS (HR: 1.29., 95% CI: 1.04-1.61, P=0.02) and CSS (HR: 1.31, 95% CI: 1.05-1.63, P=0.02). CONCLUSIONS. We found an independent association of high SII prior to CN with unfavorable clinical outcomes, particularly in patients with intermediate risk mRCC and patients with increased BMI. Despite these results, it does not seem to add any prognostic or clinical benefit beyond that obtained by currently available clinicopathologic characteristics as sole worker.
引用
收藏
页码:329 / 336
页数:8
相关论文
共 50 条
  • [21] External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model
    Chrom, Pawel
    Zolnierek, Jakub
    Bodnar, Lubomir
    Stec, Rafal
    Szczylik, Cezary
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (05) : 526 - 532
  • [22] Prognostic value of systemic immune-inflammation index in patients with gastric cancer
    Wang, Kang
    Diao, Feiyu
    Ye, Zhijun
    Zhang, Xinhua
    Zhai, Ertao
    Ren, Hui
    Li, Tong
    Wu, Hui
    He, Yulong
    Cai, Shirong
    Chen, Jianhui
    CHINESE JOURNAL OF CANCER, 2017, 36
  • [23] Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma
    Zhang, Feng
    Hu, Ke-Shu
    Lu, Shen-Xin
    Li, Miao
    Chen, Rong-Xin
    Ren, Zheng-Gang
    Shi, Ying-Hong
    Yin, Xin
    CANCER BIOMARKERS, 2021, 31 (03) : 211 - 225
  • [24] Prognostic Value of Preoperative Systemic Immune-Inflammation Index in Patients with Cervical Cancer
    Huang, Huaping
    Liu, Qin
    Zhu, Lixia
    Zhang, Yan
    Lu, Xiaojuan
    Wu, Yawei
    Liu, Li
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [25] Systemic immune-inflammation index (SII) is a useful prognostic indicator for patients with squamous cell carcinoma of the esophagus
    Feng, Ji-Feng
    Chen, Sheng
    Yang, Xun
    MEDICINE, 2017, 96 (04)
  • [26] The Value of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy
    You, Dalsan
    Jeong, In Gab
    Ahn, Jin-Hee
    Lee, Dae Ho
    Lee, Jae-Lyun
    Hong, Jun Hyuk
    Ahn, Hanjong
    Kim, Choung-Soo
    JOURNAL OF UROLOGY, 2011, 185 (01) : 54 - 59
  • [27] The Systemic Immune-Inflammation Index and Albumin as Prognostic Predictors in Laryngeal Carcinoma
    Shen, Li-Fang
    Wang, Qin-Ying
    Yu, Qi
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2021, 73 (10): : 1916 - 1923
  • [28] Prognostic implications of systemic immune-inflammation index in patients with bone metastases from hepatocellular carcinoma treated with radiotherapy
    Chen, Jingyao
    Huang, Wenhan
    Xu, Xiaohong
    Fan, Shaonan
    Zhang, Qi
    Li, Xuan
    Zeng, Zhaochong
    He, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma
    Chen, Jiabi
    He, Qingliu
    Liu, Weihui
    Li, Yining
    Zhuang, Wei
    CLINICAL INTERVENTIONS IN AGING, 2020, 15 : 431 - 439
  • [30] Predictive and Prognostic Role of Systemic Immune-Inflammation Index (SII) in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
    Malik, Mateusz
    Radecka, Barbara
    Gelej, Marek
    Jackowska, Aleksandra
    Filipczyk-Cisarz, Emilia
    Zurowska, Michalina
    Hetman, Katarzyna
    Foszczynska-Kloda, Malgorzata
    Kania-Zembaczynska, Beata
    Manka, Danuta
    Orlikowska, Marlena
    Bodnar, Lubomir
    BIOMEDICINES, 2024, 12 (09)